Peter Stratford appointed Chief Executive Officer of Adherium Limited

SYDNEY: Adherium Limited, a global leader in digital health technologies that address sub-optimal medication use in chronic disease, has appointed Peter Stratford as Chief Executive Officer (CEO), effective immediately.

Mike Motion has simultaneously been appointed Chief Commercial Officer (CCO). The transition means that interim CEO Jeremy Curnock Cook and interim CCO Bill Hunter have relinquished these roles as the company embarks on its new platform of product development and commercialisation.

Both remain as Non-executive Directors on the Adherium board. Dr Stratford has over 30 years’ experience in the pharmaceutical and medical device industries where he has led emerging and established medical device growth companies.

Most recently, Dr Stratford was Head of Innovation at BTG, which he joined in January 2011 following the acquisition of Biocompatibles International plc. Dr Stratford joined Biocompatibles in 1990 and was appointed to the Board in 2002. He took the role of Group Director Research and Development in 1998 and moved to Oncology Products and Creation as part of the Interventional Oncology business.

As Managing Director at Biocompatibles he was responsible for all aspects of development, manufacturing, regulatory and quality, working with the direct sales force and distributors in EMEA, APAC, China and Japan. At BTG he was a part of the executive leadership team managing innovation across the vascular, oncology and respiratory portfolio and was instrumental in the acquisition and integration of the key businesses in each portfolio.

Mr Motion has over 35 years’ corporate experience in medical devices and pharmaceuticals starting his commercial career at Baxter Healthcare in 1984 working in manufacturing, sales and marketing and commercial leadership roles at UK, European and global levels.

“The appointments of Peter and Mike area key step and an important phase of Adherium’s global business growth and commercialisation. This transition of control at the top of the company is a very considered step by the board,” said Mr Curnock Cook.

“This is new and top calibre experience to lead the company into its commercial growth phase to strive to deliver the promise of this technology. We welcome them to our team. Their experience with product commercialisation combined with our award-winning Hailie products and technology platform will position Adherium to grow as a market leader in digital health.”

New CEO Dr Stratford said, “Adherium has some of the best technology in this space and our goal is to bring this to a successful commercial position. I look forward to leading the organisation to bring the benefits of the Hailie solution to patients”.

Bookmark the permalink.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.